Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIENTAL: First-Line Durvalumab + Chemotherapy in Chinese ES-SCLC
NCT04449861Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2020
- Primary completion
- Mar 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab in small cell lung cancer (SCLC), sponsored by AstraZeneca. Started Dec 2020; status: completed.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04449861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04449861.